Home › Isis Pharmaceuticals secures $18 million from GSK to advance ISIS-TTR Rx Phase 2/3 study
 

Keywords :   


Isis Pharmaceuticals secures $18 million from GSK to advance ISIS-TTR Rx Phase 2/3 study

2014-10-10 04:59:10| Biotech - Topix.net

Isis Pharmaceuticals, Inc. announced today that it has earned an $18 million milestone payment from GlaxoSmithKline related to the advancement of the Phase 2/3 study of ISIS-TTRRx in patients with familial amyloid polyneuropathy . "ISIS-TTRRx is the most advanced drug in our collaboration with GSK, and aside from KYNAMRO, it is also the furthest advanced in our late-stage clinical pipeline.

Tags: study million advance phase

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
05.10Weekly Recap: BASF, Beckers, Allnex, Sherwin-Williams Top This Weeks Stories
05.10Hurricane Kirk Graphics
05.10Hurricane Kirk Forecast Discussion Number 24
05.10Hurricane Kirk Wind Speed Probabilities Number 24
05.10Hurricane Kirk Forecast Advisory Number 24
05.10Hurricane Kirk Public Advisory Number 24
05.10Summary for Hurricane Kirk (AT2/AL122024)
05.10Hurricane Leslie Graphics
More »